gsk201410276k3.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--




Publication of Supplementary Prospectus
 
The following Supplementary Prospectus dated 27 October 2014, supplementing the Base Prospectus dated 4 August 2014, has been approved by the UK Listing Authority and is available for viewing:
 
GlaxoSmithKline plc and GlaxoSmithKline Capital plc
£15,000,000,000 Euro Medium Term Note Programme
 
Copies of the Supplementary Prospectus and the documents incorporated by reference therein have been submitted to the National Storage Mechanism and will shortly be available for inspection at:
 
 
http://www.morningstar.co.uk/uk/NSM
.
 
The Supplementary Prospectus will also be available for viewing at:
 
http://www.gsk.com/en-gb/investors/stock-exchange-announcements/
 
For further information, please contact:
 
GlaxoSmithKline plc
 
980 Great West Road
 
Brentford
 
Middlesex
 
TW8 9GS
 
United Kingdom
 
 
 
Enquiries:
 
UK Media enquiries:
David Mawdsley
Simon Steel
(020) 8047 5502
(020) 8047 5502
 
European Analyst/Investor enquiries:
Gary Davies
Ziba Shamsi
 (020) 8047 5503
 (020) 8047 5543
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS AND BASE PROSPECTUS
 
Please note that the information contained in the Supplementary Prospectus and the Base Prospectus may be
addressed to and/or targeted at persons who are residents of particular
countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to
whom the offer contained in the Base Prospectus is not addressed. Prior to relying
on the information contained in the Base Prospectus you must ascertain from the Base P
rospectus whether or not you are part of the intended addressees of the
information contained therein.
Your right to access this service is conditional upon complying with the above requirements.
 

 


 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 27, 2014 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc